Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Immunology Letters|February 2, 2006
Expression and role of Fc- and complement-receptors on human dendritic cellsZsuzsa Bajtay, Eszter Csomor, Noémi Sándor, et al.
Molecular Immunology|March 27, 2007
Complement protein C1q induces maturation of human dendritic cellsEszter Csomor, Zsuzsa Bajtay, Noémi Sándor, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2026
Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results from the Phase 2 TULIP-LN TrialAndrea Fava, Michelle Petri, Patrick G Gavin, et al.
Molecular Immunology|October 18, 2008
Complement production and regulation by dendritic cells: molecular switches between tolerance and immunityCees van Kooten, Nicoletta Fiore, Leendert A Trouw, et al.
Scientific Reports|April 17, 2019
Long intergenic non-coding RNAs regulate human lung fibroblast function: Implications for idiopathic pulmonary fibrosisMarina R Hadjicharalambous, Benoit T Roux, Eszter Csomor, et al.
The Lancet. Rheumatology|November 21, 2022
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational studyKristina E N Clark, Eszter Csomor, Corrado Campochiaro, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 20, 2024
Epithelial Interleukin-1 Receptor-Like-1 Activation Is Contingent on Interleukin-33 Isoforms and Asthma-Related Receptor VariationMichael A Portelli, Maria E Ketelaar, Stewart Bates, et al.
Clinical and Experimental Rheumatology|August 17, 2024
A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationaleDinesh Khanna, Christopher P Denton, Shervin Assassi, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Annals of the Rheumatic Diseases|July 7, 2021
Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosisKristina Elizabeth Neergaard Clark, Corrado Campochiaro, Eszter Csomor, et al.
Pageof 2